Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Verstraete

Showing results (31-40 of 414) with videos related to

Pageof 42
Sort By:
Seminars in Hematology|January 1, 1978
Biochemical and clinical aspects of thrombolysisM Verstraete
European Heart Journal|July 1, 1985
Intravenous administration of a thrombolytic agent is the only realistic therapeutic approach in evolving myocardial infarctionM Verstraete
Advances in Experimental Medicine and Biology|January 1, 1992
Heparin in the prevention and treatment of arterial thromboembolismM Verstraete
Circulation|February 15, 2000
Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical developmentM Verstraete
Annals of the Academy of Medicine, Singapore|November 27, 1999
8th Seah Cheng Siang Memorial Lecture: new antithrombotic agentsM Verstraete
Annals of the Academy of Medicine, Singapore|November 27, 1999
Newer thrombolytic agentsM Verstraete
Circulation|September 1, 1990
Thrombolytic treatment in acute myocardial infarctionM Verstraete
Acta Cardiologica|June 23, 1999
Medical care in the next centuryM Verstraete
La Clinica Terapeutica|May 31, 1977
[Oral anticoagulants, dextran or low-dose subcutaneous heparin: which drug should be used for prevention of deep venous thrombosis in patients undergoing surgery?]M Verstraete
Thrombosis and Haemostasis|December 27, 1982
Registry of prospective clinical trials--fifth reportM Verstraete
Pageof 42

Showing results (31-40 of 414) with videos related to

Sort By:
Pageof 42
Seminars in Hematology|January 1, 1978
Biochemical and clinical aspects of thrombolysisM Verstraete
European Heart Journal|July 1, 1985
Intravenous administration of a thrombolytic agent is the only realistic therapeutic approach in evolving myocardial infarctionM Verstraete
Advances in Experimental Medicine and Biology|January 1, 1992
Heparin in the prevention and treatment of arterial thromboembolismM Verstraete
Circulation|February 15, 2000
Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical developmentM Verstraete
Annals of the Academy of Medicine, Singapore|November 27, 1999
8th Seah Cheng Siang Memorial Lecture: new antithrombotic agentsM Verstraete
Annals of the Academy of Medicine, Singapore|November 27, 1999
Newer thrombolytic agentsM Verstraete
Circulation|September 1, 1990
Thrombolytic treatment in acute myocardial infarctionM Verstraete
Acta Cardiologica|June 23, 1999
Medical care in the next centuryM Verstraete
La Clinica Terapeutica|May 31, 1977
[Oral anticoagulants, dextran or low-dose subcutaneous heparin: which drug should be used for prevention of deep venous thrombosis in patients undergoing surgery?]M Verstraete
Thrombosis and Haemostasis|December 27, 1982
Registry of prospective clinical trials--fifth reportM Verstraete
Pageof 42